Clinical Study

HOMA-AD in Assessing Insulin Resistance in Lean Noncirrhotic HCV Outpatients

Matheus Truccolo Michalczuk, Camila Rippol Kappel, Oscar Birkhan, Ana Carolina Braganc¸a, and M ´ario Reis ´Alvares-da-Silva

Gastroenterology Division, Hospital de Cl ´ınicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2350, 90035-803 Porto Alegre, RS, Brazil

Correspondence should be addressed to Matheus Truccolo Michalczuk, matheusm01@hotmail.com

Received 27 February 2012; Revised 22 May 2012; Accepted 22 May 2012

Academic Editor: Claudia Oliveira

Copyright © 2012 Matheus Truccolo Michalczuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. There is an association between HCV and insulin resistance (IR), which is currently assessed by HOMA-IR. There is evidence that HOMA-adiponectin (HOMA-AD) is more accurate, but its role in HCV patients is unknown. The purpose of this study was to evaluate IR in an HCV sample and controls, in order to compare the accuracy of HOMA-IR and HOMA-AD.

Methods. Ninety-four HCV outpatients aged <60 years who met the criteria of nondiabetic, nonobese, noncirrhotic, and nonalcohol abusers were included and compared to 29 controls. Fasting glucose, insulin, adiponectin, and lipid profiles were determined. IR was estimated by HOMA-IR and HOMA-AD.

Results. The groups were similar regarding sex and BMI, but the HCV patients were older. The median insulin level was higher in the HCV group (8.6 mU/mL (6.5–13.7) versus 6.5 (4.3–10.7), \(P=0.004\)), as was median HOMA-IR (1.94 (1.51 to 3.48) versus 1.40 (1.02 to 2.36), \(P=0.002\)) and the prevalence of IR (38.3% versus 10.3% \((P=0.009)\)). No differences were found in adiponectin levels \((P=0.294)\) and HOMA-AD \((P=0.393)\).

Conclusion. IR is highly prevalent even in low-risk HCV outpatients. Adiponectin is not influenced by the presence of HCV. HOMA-AD does not seem to be useful in assessing IR in HCV patients.

1. Introduction

The hepatitis C virus (HCV) is one of the most prevalent causes of chronic liver disease worldwide and leads to cirrhosis and hepatocellular carcinoma in a high percentage of carriers [1, 2]. Insulin resistance (IR), impaired glucose tolerance, and type 2 diabetes mellitus (DM) are frequent extrahepatic manifestations [3, 4]. The mechanisms by which chronic HCV infection leads to IR remain uncertain, but it has been suggested that the blockade of IRS-1 and IRS-2 signaling via proinflammatory cytokines is involved [5, 6]. Conditions other than HCV are associated with IR, which include cirrhosis [4, 7], obesity [8], and advanced age [9]. These risk factors are often present in studies focusing on IR in HCV patients.

The adipocytokines (adiponectin, leptin, and resistin) are a family of adipose tissue-derived serum proteins that influence the glucose and lipid metabolism [10]. Adiponectin (AD) modulates hepatic fat content and acts as an insulin sensitizer and an anti-inflammatory and antifibrotic cytokine [11–15]. Nonalcoholic fatty liver disease (NAFLD), a model of IR, is related to low AD levels [16–18]. Some studies have investigated the role of AD in chronic hepatitis C, but it remains controversial. Some authors suggest that HCV increases AD levels [19–22], whereas others have not corroborated these results [23–30].

IR is evaluated by the homeostasis model assessment for insulin resistance (HOMA-IR), a surrogate of the hyperinsulinemic euglycemic clamp, which is considered the standard method in IR determination [31]. HOMA-AD was recently described for assessing IR. In a general Japanese study population, selected neither by body mass index (BMI) nor glucose profile, a good correlation between HOMA-AD and clamp was shown. In addition, HOMA-AD was more accurate than HOMA-IR, especially in patients with elevated
fasting glucose levels and higher BMI [32]. The HOMA-AD index, that seems to be a reliable method in evaluating IR, has never been tested in patients with chronic hepatitis C. We hypothesized that patients with HCV, even without traditional risk factors for metabolic diseases, have a higher HOMA-IR and HOMA-AD than the control group.

2. Methods

2.1. Patients. From July 2008 to December 2009, a total of 94 consecutive outpatients with chronic HCV infection, aged between 18 and 60 years were recruited at Hospital de Clínicas de Porto Alegre (HCPA). All subjects were seropositive for HCV antibody (confirmed by third-generation enzyme-linked immunosorbent assay (ELISA) and HCV RNA PCR). Ninety-two of them (97%) were genotyped, 73 (77%) had a available viral load, and 89 (95%) had undergone liver biopsy. The other 5 (5%) had no clinical signs of cirrhosis [normal prothrombin time and platelets levels, AST/platelets rate (APRI score < 0.5), and a normal ultrasonography]. Patients with concurrent liver disease caused by something other than HCV, alcohol abusers (>40 g/day), those infected by the human immunodeficiency virus (HIV) or those presenting severe cardiovascular disorder, chronic renal injury, pancreatitis, or evidence of malignant neoplasms, including hepatocellular carcinoma were excluded. Obesity (BMI > 30), DM, and previous or actual use of interferon, immunosuppressive or cholesterol-lowering drugs were additional exclusion criteria. The Human Research and Ethics committee approved the study, and informed consent was obtained from each patient.

During the same period, 29 healthy volunteers were selected as controls at the HCPA Blood Bank. All had negative serology for HIV and chronic viral hepatitis. They met the same exclusion criteria as the exposed population.

2.2. Anthropometric Assessment. Height, weight, and waist circumference were determined by a registered dietitian. BMI was calculated by the formula weight (kg)/height (m)².

2.3. Laboratory and Histopathological Assessment. Blood samples were obtained after a 12 h overnight fasting to determine plasma glucose, insulin, and lipid profiles (total cholesterol, HDL-cholesterol, and triglycerides) and for AD analysis. Glucose and lipid profile assessments were made with the enzymatic UV-hexokinase method in Advia 1800 equipment. The plasma insulin was measured by the electrochemiluminescence method with Modular equipment by Roche, and AD was measured using ELISA commercial kits according to the manufacturer’s instructions (Adiponectin ELISA Kit, HU BioSource Europe S.A., Nivelles, Belgium).

Degree of insulin resistance was calculated according to the HOMA-IR using the following formula: fasting insulin level (mU/L) × fasting glucose level (mg/dL)/405 [30]. According to the HOMA-AD index, it was calculated by the following formula: fasting insulin level (mU/L) × fasting glucose level (mg/dL)/AD (mg/mL) [32]. A HOMA-IR index value of more than 2.71 was considered IR [33].

Ultrasound-guided liver biopsies were obtained and fragments were stained with hematoxylin-eosin. An expert pathologist assessed the biopsies according to the METAVIR scoring system. Fibrosis was staged on a scale from F0 to F4, listed as follows: F0: no fibrosis; F1: portal fibrosis, without septa; F2: few septa; F3: many septa without cirrhosis; F4: cirrhosis. Stages F0 and F1 were scored as minimal/mild fibrosis, and stages F2-F3 were scored as advanced fibrosis [34]. Patients in stage F3, if Ishak F5 (marked bridging fibrosis—incomplete cirrhosis), and those with METAVIR score of F4 (cirrhosis) were excluded from the study.

HCV carriers were divided according to the genotype and viral load into two groups: genotype 3 or non-3 and high viral load (>400.000 UI/mL) or low viral load (<400.000 UI/mL), respectively.

2.4. Statistical Analysis. Data were presented as mean ± standard deviation for variables with normal distribution and as median and interquartile range for asymmetric variables. The Student t-test or Mann-Whitney U test was used, depending on the distribution of the data (symmetrical or not) and homogeneity of variance. Categorical variables were compared by the Chi-square or Fisher’s exact test. Correlations between HOMA-IR and HOMA-AD were assessed using Spearman’s correlation coefficient analysis. All analyses were carried out using SPSS software version 11.0 (SPSS Inc., Chicago, IL, USA). All tests were two-tailed, and a P value of <0.05 was considered statistically significant.

3. Results

As shown in Table 1, regarding demographic characteristics and glucose and lipid profiles, the HCV patients were older, had lower total cholesterol, and higher insulin levels. There were no differences in gender, BMI, AD, HDL cholesterol, triglycerides or glucose levels between the groups. Table 2 shows that HOMA-IR was significantly higher in the HCV group. Also, IR was more prevalent in the HCV patients. Conversely, no difference was found between the groups concerning the HOMA-AD index.

When evaluating the HCV patients’ characteristics and their relation with IR, we found that patients with high viral load had a higher HOMA-IR when compared with those with low viral load. We could not find any influence of genotype or fibrosis on HOMA-IR (Table 3).

HOMA-IR and HOMA-AD presented a strong correlation as assessed by Spearman’s correlation coefficient analysis, varying between 0.652 in the general sample, 0.753 in noninfected individuals and 0.605 in HCV patients (P < 0.001 for all cases, as shown in Figure 1).

A logistic regression was performed to evaluate the influence of the possible confounding factors. IR was the main outcome. After the analysis, we found an odds ratio of 8.8 (1.4 to 54.9) for the association between IR and HCV. As shown in Table 4, the HCV group had higher HOMA-IR than controls, and this difference was still present after adjusting for total cholesterol, age, and BMI. The variables of total cholesterol and age did not correlate with HOMA-IR,
Table 1: Characteristics of the patients with chronic hepatitis C and controls.

| Variable                          | HCV (n = 94) | Controls (n = 29) | P value |
|----------------------------------|--------------|-------------------|---------|
| Age (years) (mean ± SD)          | 46.9 ± 8.1   | 37.5 ± 10.1       | <0.001  |
| Gender (male) (percent)          | 47 (50.5%)   | 12 (41.4%)        | 0.516   |
| Body mass index (kg/m²) (mean ± SD) | 24.7 ± 2.9  | 25.4 ± 2.8        | 0.226   |
| Glucose (mg/dL) (mean ± SD)      | 94.5 ± 10.2  | 90.6 ± 9.8        | 0.070   |
| Insulin (mU/mL) (mean ± SD)      | 8.6 ± 6.5    | 6.5 ± 4.3         | 0.004   |
| Adiponectin (mg/mL) (mean ± SD)  | 6.5 ± 3.5    | 4.6 ± 3.1         | 0.294   |
| Total cholesterol (mg/dL) (mean) | 163.4 ± 32.6 | 206.4 ± 43.9     | <0.001  |
| HDL cholesterol (mg/dL) (mean)   | 51.9 ± 15.7  | 55.9 ± 17.2       | 0.247   |
| Triglycerides (mg/dL) (mean)     | 94.5 ± 67.5  | 121.0 ± 75.0      | 0.059   |

Quantitative variables described by mean ± sd and compared by the Student t-test for independent samples or by median and interquartile range and compared by the Mann-Whitney U test, depending on the distribution of the data (symmetrical or not). Categorical variables described by n (%) and compared by the Chi-square or Fisher exact test.

Table 2: IR profile in HCV and non-HCV individuals according to HOMA-IR and HOMA-AD.

| Variable                  | HCV (n = 94) | Non-HCV (n = 29) | P value |
|---------------------------|--------------|------------------|---------|
| HOMA-IR                   | 1.9 (1.5 to 3.5) | 1.4 (1.0 to 2.4) | 0.002   |
| IR                        | 36 (38.3%)   | 3 (10.3%)        | 0.009   |
| HOMA-AD                   | 128.9 (59.1 to 369.2) | 96.7 (56.7 to 240.0) | 0.459   |

*IR defined as HOMA-IR > 2.7. Quantitative variables described by median and interquartile range and compared by the Mann-Whitney U test. Categorical variables described by n (%) and compared by Chi-square or Fisher exact test.

Table 3: HOMA-IR according to viral characteristics of patients with chronic hepatitis C.

| Variables          | N  | HOMA-IR   | P   |
|--------------------|----|-----------|-----|
| Genotype           |    |           |     |
| Non-3              | 74 | 1.94 (1.51–3.61) | 0.890 |
| 3                  | 18 | 1.93 (1.46–3.56) |       |
| Fibrosis stage*    | 89 | 1.93 (1.51–2.93) | 0.207 |
| F0/F1              | 63 | 2.75 (1.55–3.95) |       |
| F2/F3              | 26 | 1.53 (1.17–2.35) | 0.027 |
| Viral load         |    |           |     |
| >400,000 UI/mL     | 55 | 1.53 (1.17–2.35) | 0.027 |
| ≤400,000 UI/mL     | 18 | 2.21 (1.29–3.76) |       |

*META VIR.

whereas an increase of 1 kg/m² in the BMI corresponds to an increase of 0.125 units in the natural logarithm of HOMA-IR.

4. Discussion

This study was designed to evaluate the relationship between HCV, IR, and AD in a selected group of individuals with no risk factors for metabolic diseases, such as obesity and DM. Also, patients with advanced liver disease, another condition known to be associated with IR, were excluded.

AD plays a crucial role in glucose and lipid metabolism. Serum concentration of AD is inversely correlated with fat mass. Indeed, AD is downregulated in obesity and type 2 DM. The receptors involved in these processes are AdipoR1, expressed in skeletal muscle and other tissues, and AdipoR2, which is mostly localized in the liver [11–15]. Studies investigating the role of this cytokine in insulin sensitivity in HCV patients have yielded conflicting results (Table 5). These studies need to be interpreted with caution because some of them did not include a control group [19, 20, 24, 26] and some included patients with DM, cirrhosis, and obesity, the presence of which is considered to be confounding factors [19–21, 23, 24, 26–29]. Similar to the studies that included individuals with DM, obesity, and cirrhosis [22, 25], we evaluated IR by the HOMA-IR and HOMA-AD index and found differences in HOMA-IR between the groups; a result that was not achieved by Aksöz et al. [22] and Tanaka et al. [25]. Because there is strong evidence that HCV patients have more IR than controls [3, 4, 6, 21, 26, 35, 36] and the samples used by these authors were small (30 patients), the final IR and adiponectin levels could be biased.

The standard method in the IR evaluation is the hyper-insulinemic euglycemic clamp, but its cost and complexity limit its clinical applicability. HOMA-IR, the surrogate and most widely used method to assess IR, is cheap and easy to reproduce. Nevertheless, HOMA-IR has some limitations especially in patients with conditions such as impaired fasting glucose and/or high BMI. For this reason, we attempted to study the role of a new method of assessing IR: the AD-based HOMA-AD. Matsuhisla has demonstrated that HOMA-AD performs better than HOMA-IR in Japanese subjects with higher levels of glucose and elevated BMI, which suggests that HOMA-AD is promising [32]. To the best of our knowledge, HOMA-AD has never been tested in HCV patients.
HCV is associated with a specific metabolic syndrome, HCV-associated dysmetabolic syndrome, consisting of steatosis, hypocholesterolemia, and insulin resistance/diabetes. These metabolic derangements contribute to a decrease in sustained virological response (SVR) to pegylated-interferon-α-ribavirin as standard of care, and are associated with progression of liver fibrosis [37]. We found low cholesterol levels in HCV patients, as previously demonstrated [37–39]. In fact, HCV core protein reduces microsomal triglyceride transport protein function, leading to impairment of very low-density lipoprotein, triglyceride, and apolipoprotein B (APO-B) secretion, which in turn contributes to hepatic lipid accumulation and reductions in plasma total cholesterol [38].

HCV patients were compared to healthy controls. We need to address some issues regarding control group. They were younger than included HCV patients, a potential bias considering that older individuals are more prone to glucose metabolism disruptions. In order to thoroughly evaluate these differences, a multivariate analysis was performed, and the final results were not influenced by age, BMI, and total cholesterol. As a limitation to the analysis, we obtained a broad confidence interval, which can be explained by the small number of individuals in the control group with IR. Moreover, we did not rule out hepatic steatosis in control group, as they were not evaluated by ultrasound scanning. However, we have tried to minimize the possibility of NAFLD in this group, by selecting HCV negative, nonobese controls, all of them without metabolic syndrome, diabetes, or regular alcohol consumption.

Our results demonstrate that HCV patients, despite the strict inclusion criteria, have higher HOMA-IR and a higher prevalence of IR than healthy individuals. Some authors have demonstrated the same results, but they did not use the same exclusion criteria, which may have led to a possible influence of factors, such as obesity, excessive alcohol consumption, cirrhosis, and DM on the final results [21, 22, 26, 35]. The specific mechanisms by which HCV leads to
### Table 5: Main results of the studies with reference to HCV, IR, and adiponectin.

| Author, year, ref | HCV (n) | Controls (n) | Confounding factors (%) | HOMA-IR (HCV versus controls) | Adiponectin (HCV versus controls) |
|-------------------|---------|--------------|-------------------------|-----------------------------|----------------------------------|
| Lu et al., 2005 [23] | 11      | 10 HBV       | Cirrhosis (0) DM (0)     | No information             | Similar                          |
|                   |         |              | Obesity—no information   |                             |                                  |
| Aksöz et al., 2008 [22] | 30      | 30           | Cirrhosis (0) DM (0)     | Similar                     | Similar                          |
|                   |         |              | Obesity (0)              |                             |                                  |
| Tanaka et al., 2008 [25] | 30      | 30 HBV       | Cirrhosis (0) DM (0)     | Similar                     | Similar                          |
|                   |         |              | Obesity (0)              |                             |                                  |
| Cua et al., 2007 [26] | 154     | 75           | Cirrhosis (0) DM (0)     | Higher in HCV              | Similar                          |
|                   |         |              | Obesity—no information   |                             |                                  |
| Tiftikci et al., 2009 [27] | 51      | 24           | Cirrhosis (0) DM—no information | No information              | Similar                          |
|                   |         |              | Obesity—no information   |                             |                                  |
| Zografos et al., 2008 [28] | 83      | 43           | No information           | No information              | No information                   |
|                   |         |              | Cirrhosis (34)           |                             |                                  |
| Hung et al., 2009 [21] | 81      | 40           | F3/F4 DM (0)             | Higher in HCV              | Higher in HCV                   |
|                   |         |              | Obesity—no information   |                             |                                  |
| Present study/2011 | 94      | 29           | Cirrhosis (0) DM (0)     | Higher in HCV              | Higher in HCV                   |
|                   |         |              | Obesity (0)              |                             |                                  |

Glucose metabolism disturbances are not fully understood, but it seems that increased insulin resistance is associated with oxidative stress and overproduction of inflammatory cytokines. The oxidative stress mediates signals involving the p38 mitogen-activated protein kinase and activates nuclear factor kappa B. This transcription factor plays a key role in the expression of cytokines, tumor necrosis factor alpha (TNF-alpha), interleukin 6, interleukin 8, tumor growth factor beta, and Fas ligand. TNF-alpha inhibits the function of insulin receptor substrates (IRS-1) and decreases the expression of the glucose transporter (GLUT-4) and lipoprotein lipase in peripheral tissues, which leads to impaired insulin action on peripheral tissues and hepatic glucose uptake [36, 40, 41]. We recently showed that HCV-naïve patients have a higher pro-anti-inflammatory cytokines ratio than controls [42]. However, when we evaluated IR and the correlation between adiponectin and IRS-1 (measured in liver and leukocytes) in a sample of lean, nondiabetic, noncirrhotic HCV patients compared to healthy controls, we found no relationship between leukocytes and liver IRS1 and adiponectin, although there was a significant decrease of IRS-1 in patients with HCV. This finding suggests that IR is unrelated to lipid metabolism in HCV patients [43].

We can highlight some studies on HCV and IR that shared similar aims and inclusion criteria with our study. For example, Moucari et al. [44] evaluated the association between IR (HOMA-IR > 3) and HCV (genotypes and viral load) and also hepatic fibrosis. The authors found IR in 32.4% of the HCV patients, whereas we found 38.3%. Moreover, they suggested that IR is specific to HCV, especially in genotype 1 patients with a high viral load and advanced fibrosis. Similarly, we found higher HOMA-IR in patients with high viral load, but we did not observe any differences in IR, genotype or liver fibrosis. In the present study, the number of patients with advanced fibrosis was too small (just 4 patients with F3, and none cirrhotic included) to allow any conclusions. Also, a β-error may have occurred.

Another study by Vanni et al. [40] focused on the sites and mechanisms of IR (assessed by hyperinsulinemic euglycemic clamp) in 14 nonobese, nondiabetic patients with chronic HCV compared to 7 controls. The authors concluded that HCV itself is associated with peripheral and hepatic insulin resistance. They suggested that competition by increased lipid oxidation and possibly enhanced hepatic expression of inflammatory cytokines/mediators could be involved in the defective glucose regulation. Compared to these trials, we found similar results regarding the relationship of IR and HCV, but we demonstrated that HCV could exert this effect despite lipid metabolism.

In fact, we did not find differences between the groups regarding AD levels. The strict inclusion criteria (lean patients, no DM or cirrhosis) can partly explain these results. On the other hand, mechanisms of IR in HCV patients may be different from those related to other diseases, such as...
NAFLD. Regarding relation between hepatic steatosis and adiponectin in our sample, some individuals in the HCV group were not evaluated by US scanning and just a few (six patients) had hepatic steatosis at liver biopsy, which made it difficult to assess this relationship. When we considered the influence of AD on the IR assessed by HOMA-AD, no difference was observed between the HCV patients and individuals unexposed to the virus. The discrepancy between the results obtained by HOMA-IR and HOMA-AD can be explained by the absence of a direct effect of HCV on AD. It seems that AD does not influence IR in lean HCV patients. Finally, despite the fact that HOMA-IR and HOMA-AD showed a good correlation, the results they yielded were not concordant. This seems to have occurred because both indexes include glucose and insulin in their formula and AD has a minor influence on the mathematical correlation.

In conclusion, HCV is related to IR even in the absence of obesity, DM, and cirrhosis, and it does not seem to be AD-dependent. Even though HOMA-AD is a promising method to assess IR in other conditions, it cannot be recommended for the evaluation of IR in the HCV population. We suggest that HCV patients, independent of risk factors for metabolic diseases, should be evaluated for IR. However, HOMA-IR cannot be replaced by HOMA-AD in the assessment of IR in HCV-infected patients.

Acknowledgment

The research project was fully sponsored by FIPE (Fundo de Incentivo à Pesquisa do Hospital de Clínicas de Porto Alegre).

References

[1] L. B. Seeff, Z. Buskell-Bales, E. C. Wright et al., “Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group,” The New England Journal of Medicine, vol. 327, pp. 1906–1911, 1992.

[2] T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997.

[3] R. Narita, S. Abe, Y. Kihara, T. Akiyama, A. Tabaru, and M. Otsuki, “Insulin resistance and insulin secretion in chronic hepatitis C virus infection,” Journal of Hepatology, vol. 41, no. 1, pp. 132–138, 2004.

[4] A. Lonardo, L. E. Adinolfi, S. Petta, A. Craxi, and P. Loria, “Hepatitis C and diabetes: the inevitable coincidence?” Expert Review of Anti-Infecive Therapy, vol. 7, no. 3, pp. 293–308, 2009.

[5] K. Moriya, H. Yotsuyanagi, Y. Shintani et al., “Hepatitis C virus core protein induces hepatic steatosis in transgenic mice,” Journal of General Virolology, vol. 78, no. 7, pp. 1527–1531, 1997.

[6] S. Ayug, D. Reich, L. E. Sapino, D. Bernstein, and N. Begum, “Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes,” Hepatology, vol. 36, no. 6, pp. 1384–1392, 2003.

[7] D. Mutting, N. Lackas, H. Reikowski, and S. Rismon, “Cirrhosis of the liver and diabetes mellitus. A study of 140 combined cases,” German Medical Monthly, vol. 11, pp. 385–390, 1966.

[8] B. Antuna-Puente, B. Feve, S. Fellahi, and J. P. Bastard, “Adipokines: the missing link between insulin resistance and obesity,” Diabetes & Metabolism, vol. 34, no. 1, pp. 2–11, 2008.

[9] L. K. Chen, Y. M. Chen, M. H. Lin, L. N. Peng, and S. J. Hwang, “Care of elderly patients with diabetes mellitus: a focus on frailty,” Ageing Research Reviews, vol. 9, supplement 1, pp. S18–S22, 2010.

[10] A. G. Pittas, N. A. Joseph, and A. S. Greenberg, “Adipocytokines and insulin resistance,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, pp. 447–452, 2004.

[11] Y. Matsuzawa, T. Funahashi, S. Kihara, and I. Shimomura, “Adiponectin and the metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 1, pp. 29–33, 2004.

[12] A. Lopez-Bermejo, P. Botas, T. Funahashi et al., “Adiponectin, hepatocellular dysfunction and insulin sensitivity,” Clinical Endocrinology, vol. 60, pp. 256–263, 2004.

[13] Y. Kamada, S. Tamura, S. Kiso et al., “Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin,” Gastroenterology, vol. 125, no. 6, pp. 1796–1807, 2003.

[14] A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, “The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice,” Journal of Clinical Investigation, vol. 112, no. 1, pp. 91–100, 2003.

[15] T. Masaki, S. Chiba, H. Tatsukawa et al., “Adiponectin protects LPS-induced liver injury through modulation of TNF-α in KK-Ay obese mice,” Hepatology, vol. 40, no. 1, pp. 177–184, 2004.

[16] A. J. McCullough, “Pathophysiology of nonalcoholic steatohepatitis,” Journal of Clinical Gastroenterology, vol. 40, supplement 1, pp. S17–S29, 2006.

[17] R. S. Ahima, “Insulin resistance: cause or consequence of nonalcoholic steatohepatitis?” Gastroenterology, vol. 132, no. 1, pp. 444–446, 2007.

[18] F. Marra and C. Bertolani, “Adipokines in liver diseases,” Hepatology, vol. 50, no. 3, pp. 957–969, 2009.

[19] C. J. Liu, P. J. Chen, Y. M. Jeng et al., “Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C,” Journal of Hepatology, vol. 43, no. 2, pp. 235–242, 2005.

[20] E. Durante-Mangoni, R. Zampino, A. Marrone et al., “Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-α in chronic hepatitis C patients,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 9, pp. 1349–1357, 2006.

[21] C. H. Hung, C. M. Lee, C. H. Chen et al., “Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C,” Liver International, vol. 29, no. 7, pp. 1086–1093, 2009.

[22] K. Aksöz, B. Unsal, A. Kirici et al., “The relationship between chronic HCV infection and the level of plasma adiponectin,” Turkish Journal of Gastroenterology, vol. 19, no. 4, pp. 254–257, 2008.

[23] J. Y. Lu, L. M. Chuang, W. S. Yang et al., “Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-α therapy,” Liver International, vol. 25, no. 4, pp. 752–759, 2005.

[24] S. Sato, K. Furuta, T. Mishiro et al., “Serum adiponectin concentration in patients with hepatitis C virus,” Journal of Clinical Gastroenterology, vol. 39, no. 8, pp. 744–745, 2005.
[25] N. Tanaka, T. Nagaya, M. Komatsu et al., “Insulin resistance and hepatitis C virus: a case-control study of non-obese, non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase,” *Liver International*, vol. 28, no. 8, pp. 1104–1111, 2008.

[26] I. H. Y. Cua, J. M. Hui, P. Bandara et al., “Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines,” *Hepatology*, vol. 46, no. 1, pp. 66–73, 2007.

[27] A. Tiftikci, O. Atug, Y. Yilmaz et al., “Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis,” *Archives of Medical Research*, vol. 40, no. 4, pp. 294–298, 2009.

[28] T. A. Zografos, C. Liaskos, E. I. Rigopoulou et al., “Adiponectin: a new independent predictor of liver steatosis and response to IFN-α treatment in chronic hepatitis C,” *American Journal of Gastroenterology*, vol. 103, no. 4, pp. 605–614, 2008.

[29] M. Grigorescu, C. Radu, D. Crisan et al., “Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C,” *Journal of Gastrointestinal and Liver Diseases*, vol. 17, no. 2, pp. 147–154, 2008.

[30] A. Y. H. Wang, I. J. Hickman, A. A. Richards, J. P. Whitehead, J. B. Prins, and G. A. MacDonald, “High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection,” *American Journal of Gastroenterology*, vol. 100, no. 12, pp. 2717–2723, 2005.

[31] D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” *Diabetologia*, vol. 28, no. 7, pp. 412–419, 1985.

[32] M. Matsuhisa, Y. Yamasaki, M. Emoto et al., “A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects,” *Diabetes Research and Clinical Practice*, vol. 77, pp. 151–154, 2007.

[33] B. Geloneze, E. M. Repetto, S. R. Geloneze, M. A. Tambascia, and M. N. Ermetice, “The threshold value for insulin resistance (HOMA-IR) in an admixed population. IR in the Brazilian Metabolic Syndrome Study,” *Diabetes Research and Clinical Practice*, vol. 72, no. 2, pp. 219–220, 2006.

[34] The French META VIR Cooperative Study Group, “Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C,” *Hepatology*, vol. 20, no. 2, pp. 15–20, 1994.

[35] F. Imazeki, O. Yokosuka, K. Fukai, T. Kanda, H. Kojima, and H. Saisho, “Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients,” *Liver International*, vol. 28, no. 3, pp. 355–362, 2008.

[36] A. Lecube, C. Hernández, J. Genescà, and R. Simó, “Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis,” *Diabetes Care*, vol. 29, no. 5, pp. 1140–1149, 2006.

[37] L. E. Adinolfi, L. Restivo, R. Zampino et al., “Metabolic alterations and chronic hepatitis C: treatment strategies,” *Expert Opinion on Pharmacotherapy*, vol. 12, pp. 2215–2234, 2011.

[38] F. Negro and A. J. Sanyal, “Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data,” *Liver International*, vol. 29, no. 2, pp. 26–37, 2009.

[39] A. Mostafa, M. K. Mohamed, M. Saeed et al., “Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors,” *Gut*, vol. 59, no. 8, pp. 1135–1140, 2010.

[40] E. Vanni, M. L. Abate, E. Gentilcore et al., “Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C,” *Hepatology*, vol. 50, no. 3, pp. 697–706, 2009.

[41] M. Y. Sheikh, J. Choi, I. Qadri, J. E. Friedman, and A. J. Sanyal, “Hepatitis C virus infection: molecular pathways to metabolic syndrome,” *Hepatology*, vol. 47, no. 6, pp. 2127–2133, 2008.

[42] C. P. Oliveira, C. R. Kappel, M. R. Alvares-da-Silva et al., “Effects of Hepatitis C virus on cardiovascular risk in infected patients: a comparative study,” *International Journal of Cardiology*. In press.

[43] M. Michalczuk, C. R. Kappel, and M. R. Alvares-da-Silva, “HOMA-IR vs HOMA-AD and liver and leukocytes IRS1 in assessing insulin resistance (IR) in lean naïve HCV-infected patients: more than lipid metabolism is involved,” *Journal of Hepatology*, vol. 54, p. S449, 2011.

[44] R. Moucari, T. Asselah, D. Gazals-Hatem et al., “Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis,” *Gastroenterology*, vol. 134, no. 2, pp. 416–423, 2008.